J Cancer 2020; 11(4):837-848. doi:10.7150/jca.35011 This issue


STAT3 signaling in ovarian cancer: a potential therapeutic target

Renba Liang, Xishan Chen, Li Chen, Fangzhu Wan, Kaihua Chen, Yongchu Sun, Xiaodong Zhu

Department of Radiation Oncology, Guangxi Medical University Cancer Hospital and Cancer Institute of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, P.R. China

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Liang R, Chen X, Chen L, Wan F, Chen K, Sun Y, Zhu X. STAT3 signaling in ovarian cancer: a potential therapeutic target. J Cancer 2020; 11(4):837-848. doi:10.7150/jca.35011. Available from https://www.jcancer.org/v11p0837.htm

File import instruction


Accumulating evidence has shown that Signal Transducer and Activator of Transcription 3 (STAT3) is thought to be a promising target for cancer therapy as STAT3 is frequently overexpressed in a wide range of cancer cells as well as clinical specimens, promoting tumor progression. It is widely accepted that STAT3 regulates a variety of cellular processes, such as tumor cell growth, survival, invasion, cancer stem cell-like characteristic, angiogenesis and drug-resistance. In this review, we focus on the role of STAT3 in tumorigenesis in ovarian cancer and discuss the existing inhibitors of STAT3 signaling that can be promisingly developed as the strategies for ovarian cancer therapy.

Keywords: STAT3, ovarian cancer, tumorigenesis, inhibitors